Dollar Amounts
USD (Millions)
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Assets | $2,794 | $3,314 | $3,617 | $3,830 | $3,643 |
| Liabilities | $939 | $978 | $932 | $949 | $961 |
| Equity | $1,855 | $2,335 | $2,685 | $2,881 | $2,682 |
Balance sheet data in USD (millions)
Doing some research...
Edwyn
Over the past 5 years, West Pharmaceutical Services, Inc. has shown consistent growth in its financial position. Total assets have been steadily increasing from $2.8 billion in 2020 to $3.6 billion in 2022, before experiencing a slight decline in 2024 to $3.6 billion. This growth indicates the company's expansion and investment in its operations. Total liabilities have remained relatively stable, with a slight increase in 2024, reflecting a conservative approach to debt management. Stockholders' equity has seen significant growth, reaching $2.7 billion in 2024, showcasing the company's ability to generate profits and retain earnings. Noteworthy fluctuations include the increase in equity from 2020 to 2022, which outpaced the growth in assets, indicating improved profitability and efficiency in managing resources. The decline in assets in 2024 may be due to strategic decisions such as divestitures or changes in business focus. Overall, West Pharmaceutical Services, Inc. appears to be in a healthy financial position, with a strong balance sheet and solid equity base. In the context of the pharmaceutical industry, this stability and growth bode well for the company's ability to navigate challenges and capitalize on opportunities in a competitive market.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.